Cognitive Performance in Parkinson’s Linked to Sleep Efficiency, Study Shows

University of São Paulo researchers have found that Parkinson’s patients with dementia sleep less and less efficiently, which affects their overall cognitive performance. The study with that finding, “Global cognitive performance is associated with sleep efficiency measured by polysomnography in patients with Parkinson’s disease,” was published in Psychiatry and Clinical Neurosciences. Non-motor complications associated with

Being Still Reveals Many Treasures

It is quiet behind our house this time of year. Not many people are using the pathway that stretches from one town to another. It is cold outside and it pierces my flesh, leaving me shivering as Ip stand and wait. In the silence, I can hear my teeth chatter. So, what compels me to stand out in

Smartphone App Can Identify Early Symptoms of Motor Disorders, Study Reports

A smartphone application using a touch-based model is able to accurately identify early signs of motor disorders, according to a new study. The app, developed for patients with Huntington’s disease, is also intended for people with Parkinson’s and other neurological disorders. The study, “A smartphone application for automated decision support in cognitive task based evaluation

Nuedexta Often Used to Treat Symptoms of Parkinson’s and Dementia Off-label, Study Finds

An oral medicine approved to treat pseudobulbar affect — involuntary outbursts of laughing or crying — in people with amyotrophic lateral sclerosis  or multiple sclerosis  is most often prescribed to treat those with Parkinson’s disease or dementia, a study based on U.S. health databases reports. The study “Assessment of Use of Combined Dextromethorphan and Quinidine in Patients With

Sirion and Denali Collaborating to Develop Gene Therapies for Neurodegenerative Diseases

Sirion Biotech and Denali Therapeutics have agreed to partner on the development of gene therapies for Parkinson’s disease and other neurodegenerative disorders. According to the license and collaboration agreement, the two companies will pursue the development of harmless, next-generation adeno-associated viral vectors (AAV) able to cross the blood-brain barrier — a semipermeable membrane that protects the brain against